SAN DIEGO, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced results from multiple studies that showed the positive impact of ManoScan® high resolution manometry and Bravo® pH monitoring in measuring esophageal dysfunction and the severity of symptoms including dysphagia, chest pain and reflux. The studies were presented during the American College of Gastroenterology's 2013 Annual Scientific Meeting (ACG), taking place October 11-16, 2013 in San Diego, California where Given Imaging is exhibiting at booth #1200 throughout the conference.
Highlights of key studies presented at ACG include:
•Repeat esophageal manometry positively impacts diagnostic management in 57.6% of patients•ManoScan provides valuable insights about opioid induced esophageal dysfunction, a condition for which limited data was previously available•High resolution manometry finds a higher rate of achalasia in African American women as compared to other races/ethnicities in the largest multi-ethnic cohort evaluated to date•Bravo pH monitoring helps redirect care in 95% of patients with esophageal symptoms who didn't respond to high dose PPI therapy
"Determining the correspondence between esophageal disorders and their underlying causes can be difficult due to the overlapping symptoms of many gastrointestinal conditions," said John Pandolfino, M.D., Chief, Division of Medicine-Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine. "Using ManoScan high resolution manometry and Bravo pH monitoring, we can now pinpoint the underlying causes of a patient's symptoms, determine a patient's condition, and tailor therapies to ultimately improve patient outcomes."
Dr. John Pandolfino and colleagues at Northwestern University, presented poster #P29, "The Natural History of Esophagogastric Junction Outflow Obstruction and Treatment Outcomes," and discussed how patients with this condition, as diagnosed by high resolution manometry, present with dysphagia as the predominant symptom (46%), followed by chest pain (32%), heartburn (20%), or nausea and vomiting (19%). More patients reported improvement in symptoms with treatment, but additional prospective studies are needed to evaluate the effect of different treatment modalities on patient outcomes.
In addition, high resolution manometry was also evaluated in specific patient sub-populations including the elderly and chronic opioid users. In poster #P1216, "Alterations in Esophageal Function on High Resolution Esophageal Manometry in the Elderly," Steven DeMeester M.D., and colleagues at the Keck School of Medicine of the University of Southern California performed an analysis of 164 patients who underwent high resolution manometry and found that abnormal peristaltic breaks were observed in more patients over 70 years of age (44% vs. 10%) and were more common in patients with GERD and dysphagia symptoms. The authors noted that the decline in esophageal body function with age did not appear to be related to the severity of GERD and should be considered when discussing treatment options and expected outcomes in patients 70 years or older.